Novo Nordisk A/S stated it’s going to take an impairment of about 5.7 billion Danish kroner ($820 million) after halting a late-stage examine of an experimental coronary heart drug it acquired final yr.
The Danish drugmaker stopped the trial partway by means of, after an unbiased monitoring committee concluded that it hadn’t hit its primary aim of fixing blood strain after 12 weeks. The examine of greater than 600 sufferers, Clarion-CKD, had seemed on the compound ocedurenone in sufferers with uncontrolled hypertension and superior continual kidney illness.
Novo agreed final yr to pay KBP BioSciences as a lot as $1.3 billion for ocedurenone, a part of the Ozempic maker’s effort to increase from its core diabetes remedy portfolio into different critical illnesses.
The failure is a uncommon setback for Novo, which is driving excessive on the success of its weight problems medication.
The drugmaker had envisioned ocedurenone addressing a serious want for folks with each coronary heart illness and continual kidney illness, its executives stated when the deal was introduced in October. The corporate had deliberate to check the compound throughout several types of coronary heart and kidney illness. Novo is now re-evaluating that plan, it stated Wednesday.
The failed compound is a part of a brand new class of tablets referred to as non-steroidal mineralocorticoid receptor antagonists, or nsMRAs, that features Bayer AG’s predicted blockbuster Kerendia.
Novo shares traded as a lot as 2.4% decrease in Copenhagen. The inventory has soared greater than 40% this yr.
